RG6182
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 04, 2026
Exploring the Potential of Combination Therapy to Tackle MS Progression: Design of the Phase II MINTAKA Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of the Oral Monoacylglycerol Lipase Inhibitor RG6182 as an Add-On to Ocrelizumab in People With Progressive Multiple Sclerosis
(ACTRIMS Forum 2026)
- P3 | "MINTAKA is the first Phase II study in pwPMS to test a combination of highly effective disease-modifying therapy and an add-on agent (RG6182) with a novel mechanism that has the potential to address the key unmet need of residual progression in PMS."
Clinical • Combination therapy • P2 data • PK/PD data • CNS Disorders • Inflammation • Multiple Sclerosis
1 to 1
Of
1
Go to page
1